Study of ASN004 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Participants in this study will receive ASN004 once every 3 weeks by intravenous infusion.
The study will test various doses of ASN004 to find out the highest safe dose to test in
future trials.
Eligible subjects will be sequentially enrolled in cohorts at escalated doses. There will be
up to 43 evaluable patients in about seven dose levels with up to six subjects per dose
level.